Aankondiging • Jul 15
KBIO LABS Inc. announced that it has received KRW 2.000000184 billion in funding from Mirae I&G Co., Ltd. On July 14, 2026, KBIO LABS Inc. has closed the transaction. Aankondiging • Jul 07
KBIO LABS Inc. announced that it expects to receive KRW 2.000000184 billion in funding from Mirae I&G Co., Ltd. KBIO LABS Inc announced a private placement to issue 2,747,253 common shares at an issue price of KRW 728 for the proceeds of KRW 2,000,000,184 on July 6, 2026. Transaction involves participation of Mirae I&G Co., Ltd. as an investor. Transaction is approved by board of directors and is expected to close by July 14, 2026. Shares are restricted for 1 year from closing. Aankondiging • Feb 26
KBIO COMPANY Inc., Annual General Meeting, Mar 31, 2026 KBIO COMPANY Inc., Annual General Meeting, Mar 31, 2026, at 08:30 Tokyo Standard Time. Location: conference room, 375, sowol-ro, yongsan-gu, seoul South Korea New Risk • Feb 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩43.3b market cap, or US$29.7m). New Risk • Aug 30
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (28% accrual ratio). Minor Risk Market cap is less than US$100m (₩31.8b market cap, or US$22.9m). Buy Or Sell Opportunity • Jun 30
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 9.8% to ₩257. The fair value is estimated to be ₩214, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Earnings per share has grown by 49%. Reported Earnings • Mar 22
Full year 2024 earnings released: ₩59.00 loss per share (vs ₩116 loss in FY 2023) Full year 2024 results: ₩59.00 loss per share (improved from ₩116 loss in FY 2023). Revenue: ₩76.5b (up 180% from FY 2023). Net loss: ₩6.79b (loss narrowed 43% from FY 2023). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. Aankondiging • Mar 12
KBIO COMPANY Inc., Annual General Meeting, Mar 26, 2025 KBIO COMPANY Inc., Annual General Meeting, Mar 26, 2025, at 08:30 Tokyo Standard Time. Location: conference room, 375, sowal-ro, yongsan-gu, seoul South Korea New Risk • Jan 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩33.8b market cap, or US$23.2m). Valuation Update With 7 Day Price Move • Jan 08
Investor sentiment improves as stock rises 33% After last week's 33% share price gain to ₩293, the stock trades at a trailing P/E ratio of 21.2x. Average trailing P/E is 16x in the Semiconductor industry in South Korea. Total loss to shareholders of 77% over the past three years. New Risk • Dec 07
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (28% accrual ratio). Minor Risk Market cap is less than US$100m (₩27.0b market cap, or US$19.0m). New Risk • Aug 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 7.1% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩42.6b market cap, or US$31.5m). New Risk • Nov 28
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 24% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩34.9b market cap, or US$26.9m). New Risk • Aug 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩43.1b market cap, or US$32.7m). Board Change • Jul 21
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Jun 15
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 20
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Aankondiging • Apr 10
Gold Pacific Co., Ltd. announced that it has received KRW 8.001 billion in funding from Elim Corporation On April 9, 2021, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction. Is New 90 Day High Low • Mar 03
New 90-day low: ₩1,335 The company is down 18% from its price of ₩1,630 on 03 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Semiconductor industry, which is up 25% over the same period. Aankondiging • Jan 23
Gold Pacific Co., Ltd. announced that it has received KRW 10 billion in funding On January 22, 2021, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.. The conversion of bonds will start on January 22, 2022 and end on December 22, 2023. The maturity date of bonds has changed to January 22, 2024. Aankondiging • Jan 20
Gold Pacific Co., Ltd. announced that it expects to receive KRW 10 billion in funding Gold Pacific Co., Ltd. (KOSDAQ:A038530) announced a private placement of Series 25 Non-Guaranteed private equity bond with underwriting rights for gross proceeds of KRW 10,000,000,000 on January 19, 2021. The transaction will include participation from Macrona Fund for 7,000,000,000 bonds and individual investor Kim Hooseong for 3,000,000,000. The bonds bear a fixed coupon rate of 1% and interest rate to maturity of 1%. The bonds will mature on February 2, 2024. The bonds are 100% convertible at a fixed conversion price of KRW 1,571 per share into 6,365,372 shares from February 2, 2022 to January 2, 2024. The subscription date of the bonds is January 21, 2021 and the payment date if February 2, 2021. Is New 90 Day High Low • Jan 11
New 90-day low: ₩1,355 The company is down 40% from its price of ₩2,265 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Semiconductor industry, which is up 43% over the same period. Aankondiging • Oct 13
Gold Pacific Co., Ltd. announced that it expects to receive KRW 10.000084 billion in funding Gold Pacific Co., Ltd. (KOSDAQ:A038530) announced private placement of 6,046,000 shares at a price of KRW 1,654 per share for gross proceeds of KRW 10,000,084,000 with Kaid Fund on October 12, 2020. The expected payment date is April 09, 2021. The shares are subject to lock up for 1 year. The transaction is approved by the board of directors of the company. Is New 90 Day High Low • Oct 08
New 90-day high: ₩1,985 The company is up 32% from its price of ₩1,505 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Semiconductor industry, which is up 4.0% over the same period. Aankondiging • Sep 22
Gold Pacific Co., Ltd. announced that it has received KRW 10 billion in funding from Chorokbaem Media Co., Ltd., Philosys Healthcare Co., Ltd On September 17, 2020, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction. Aankondiging • Sep 09
Gold Pacific Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Chorokbaem Media Co., Ltd., Philosys Healthcare Co., Ltd Gold Pacific Co., Ltd. (KOSDAQ:A038530) announced that it will receive KRW 10,000,000,000 in a round of funding on September 8, 2020. The company will issue series 24 unregistered non-guaranteed coupon private convertible bonds in the transaction. The transaction will include participation from Chorokbaem Media Co., Ltd. (KOSDAQ:A047820) for KRW 5,000,000,000 and Philosys Healthcare Co., Ltd (KOSDAQ:A057880) for KRW 5,000,000,000. The bonds bear a fixed coupon rate of 1% and yield to maturity rate of 1%. The bonds will mature on September 17, 2023. The bonds are fully convertible at fixed conversion price of KRW 1,419 per share into 7,047,216 common shares from September 17, 2021 to August 17, 2023. The subscription date of the bonds is September 10, 2020 and the payment date of the bonds is September 17, 2020. The transaction was approved by the board of directors of the company. 
